专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080070887A1 Diaryl Ether Derivatives and Uses Thereof 失效
标题翻译：二芳基醚衍生物及其用途
公开(公告)号：US20080070887A1
公开(公告)日：2008-03-20
申请号：US11852358
申请日：2007-09-10
申请人： Roger Ruggeri , George Magnus-Aryitey
发明人： Roger Ruggeri , George Magnus-Aryitey
IPC分类号： A61K31/397 , A61K31/164 , A61K31/165 , A61K31/34 , A61K31/4164 , A61K31/4523 , A61P3/10 , C07C215/00 , C07D213/02 , C07D309/02 , C07D307/02 , C07C233/00 , A61P43/00 , A61K31/505 , A61K31/44 , A61K31/415 , A61K31/343 , A61K31/351
CPC分类号： C07D307/14 , C07C235/60 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D213/38 , C07D309/04
摘要： Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described herein. where R1, R2, R3, R4, R5, and R6 are described herein.
摘要翻译：在本文中描述了在mu，κ和/或δ阿片受体上作为拮抗剂并因此可用于治疗受益于动物中的这种拮抗作用的疾病，病症和/或病症的式（I）化合物。其中R 1，R 2，R 3，R 4，R 5，，和R 6 6。

2. 发明申请

US20070004774A1 Cept inhibitors and metabolites thereof 审中-公开
标题翻译：抗抑郁剂及其代谢物
公开(公告)号：US20070004774A1
公开(公告)日：2007-01-04
申请号：US10579898
申请日：2004-09-30
申请人： Deepak Dalvie , Roger Ruggeri
发明人： Deepak Dalvie , Roger Ruggeri
IPC分类号： A61K31/4706 , C07D215/38
CPC分类号： C07C309/15 , C07D215/06 , C07D215/08 , C07D215/12 , C07D215/14 , C07D215/42 , C07D215/48
摘要： Compounds resulting from the administration of torcetrapib to a mammal, and the use of such compounds as an indicator or biomarker to the presence or exposure of torcetrapib in the plasma of a mammal including humans. The invention is also directed to cholesteryl ester transfer protein (CETP) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein (HDL)-cholesterol and to lower certain other plasma lipid levels, such as low density lipoprotein (LDL)-cholesterol and triglycerides.
摘要翻译：由torcetrapib给哺乳动物产生的化合物，以及这些化合物作为指示剂或生物标志物在哺乳动物包括人类血浆中的存在或暴露的用途。本发明还涉及胆固醇酯转移蛋白（CETP）抑制剂，含有这些抑制剂的药物组合物，以及这些抑制剂用于提高某些血浆脂质水平（包括高密度脂蛋白（HDL） - 胆固醇）并降低某些其它血浆脂质水平，如低密度脂蛋白（LDL） - 胆固醇和甘油三酸酯。

3. 发明申请

US20060122224A1 Quinoline and quinoxaline compounds 审中-公开
标题翻译：喹啉和喹喔啉化合物
公开(公告)号：US20060122224A1
公开(公告)日：2006-06-08
申请号：US11305874
申请日：2005-12-15
申请人： Bruce Bechle , George Chang , Mary Diduik , Jari Finneman , Ravi Garigipati , Rayn Kelley , David Perry , Michael Pollastri , Roger Ruggeri
发明人： Bruce Bechle , George Chang , Mary Diduik , Jari Finneman , Ravi Garigipati , Rayn Kelley , David Perry , Michael Pollastri , Roger Ruggeri
IPC分类号： A61K31/47 , C07D215/38
CPC分类号： C07D401/04 , C07D215/12 , C07D215/14 , C07D241/42 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/10 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/10 , C07D413/12 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/04 , C07D495/04
摘要： Quinoline and quinoxaline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
摘要翻译：喹啉和喹喔啉化合物，含有这些化合物的药物组合物以及使用这些化合物来提高某些血浆脂质水平，包括高密度脂蛋白胆固醇和降低某些其他血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酸酯，从而治疗疾病这些由于低水平的HDL胆固醇和/或高水平的LDL-胆固醇和甘油三酸酯而加剧，如一些哺乳动物，包括人类的动脉粥样硬化和心血管疾病。

4. 发明申请

US20060063803A1 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds 审中-公开
标题翻译： 4-氨基取代-2-取代-1,2,3,4-四氢喹啉化合物
公开(公告)号：US20060063803A1
公开(公告)日：2006-03-23
申请号：US11187854
申请日：2005-07-25
申请人： Roger Ruggeri , George Magnus-Aryitey , Ravi Shanker , Douglas Lorenz , Cheryl Garr
发明人： Roger Ruggeri , George Magnus-Aryitey , Ravi Shanker , Douglas Lorenz , Cheryl Garr
IPC分类号： A61K31/4709 , C07D403/04
CPC分类号： C07D401/12 , C07D215/42 , C07D401/14 , C07D405/14
摘要： 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
摘要翻译： 4-氨基取代-2-取代-1,2,3,4-四氢喹啉化合物，含有这些化合物的药物组合物，以及使用这些化合物来提升某些血浆脂质含量，包括高密度脂蛋白胆固醇和降低某些其他血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并因此治疗由低水平的HDL胆固醇和/或高水平的低密度脂蛋白胆固醇和甘油三酯，如一些哺乳动物，包括人类的动脉粥样硬化和心血管疾病而加重的疾病。

5. 发明授权

US06713489B2 7-[(4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B 失效
标题翻译： 7 - [（4'-三氟甲基 - 联苯-2-羰基）氨基] - 喹啉-3-羧酸酰胺，以及抑制载脂蛋白B分泌的方法
公开(公告)号：US06713489B2
公开(公告)日：2004-03-30
申请号：US10054455
申请日：2002-01-22
申请人： Roger Ruggeri , Douglas Wilson
发明人： Roger Ruggeri , Douglas Wilson
IPC分类号： A61K3147
CPC分类号： C07D405/14 , C07D215/54 , C07D401/12 , C07D401/14 , C07D409/12
摘要： This invention relates to compounds of Formula I: that inhibit the secretion of apolipoprotein B, to pharmaceutical compositions comprising the compounds, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperliproproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X. This invention also relates to methods of reducing the secretion of apolipoprotein B and/or inhibiting microsomal triglyceride transfer protein.
摘要翻译：本发明涉及式I化合物：抑制载脂蛋白B分泌到包含该化合物的药物组合物，以及治疗和/或预防动脉粥样硬化，肥胖，糖尿病，高脂血症，高脂蛋白血症，高胆固醇血症，高甘油三酯血症，低脂蛋白血症，胰腺炎的方法，心肌梗塞，中风，再狭窄或X综合症。本发明还涉及减少载脂蛋白B分泌和/或抑制微粒体甘油三酯转运蛋白的方法。

6. 发明申请

US20060247272A1 4-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline Compounds 审中-公开
标题翻译： 4-氨基取代的2-取代的-1,2,3,4-四氢喹啉化合物
公开(公告)号：US20060247272A1
公开(公告)日：2006-11-02
申请号：US11424601
申请日：2006-06-16
申请人： Roger Ruggeri , George Magnus-Aryitey , Ravi Shanker , Douglas Lorenz , Cheryl Garr
发明人： Roger Ruggeri , George Magnus-Aryitey , Ravi Shanker , Douglas Lorenz , Cheryl Garr
IPC分类号： A61K31/4706 , C07D215/38
CPC分类号： C07D401/12 , C07D215/42 , C07D401/14 , C07D405/14
摘要： 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
摘要翻译： 4-氨基取代-2-取代-1,2,3,4-四氢喹啉化合物，含有这些化合物的药物组合物，以及使用这些化合物来提升某些血浆脂质含量，包括高密度脂蛋白胆固醇和降低某些其他血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并因此治疗由低水平的HDL胆固醇和/或高水平的低密度脂蛋白胆固醇和甘油三酯，如一些哺乳动物，包括人类的动脉粥样硬化和心血管疾病而加重的疾病。

7. 发明申请

US20060211654A1 Pharmaceutical Compositions of Cholesteryl Ester Transfer Protein Inhibitor 有权
标题翻译：胆固醇酯转运蛋白抑制剂的药物组合物
公开(公告)号：US20060211654A1
公开(公告)日：2006-09-21
申请号：US11421888
申请日：2006-06-02
申请人： William Curatolo , Dwayne Friesen , Michael Gumkowski , Douglas Lorenz , James Nightingale , Roger Ruggeri , Ravi Shanker
发明人： William Curatolo , Dwayne Friesen , Michael Gumkowski , Douglas Lorenz , James Nightingale , Roger Ruggeri , Ravi Shanker
IPC分类号： A61K31/717 , A61K31/21 , A61K31/165
CPC分类号： A61K9/1652 , A61K9/146 , A61K9/1635 , A61K31/4196 , A61K31/47
摘要： A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
摘要翻译：药物组合物包含胆固醇酯转移蛋白抑制剂和浓度增强聚合物的固体无定形分散体。

8. 发明申请

US20060128751A1 CETP inhibitors in combination with antihypertensive agents and uses thereof 审中-公开
标题翻译： CETP抑制剂与抗高血压药物的组合及其用途
公开(公告)号：US20060128751A1
公开(公告)日：2006-06-15
申请号：US11345796
申请日：2006-02-01
申请人： Roger Ruggeri
发明人： Roger Ruggeri
IPC分类号： A61K31/4706
CPC分类号： A61K45/06 , A61K31/00 , A61K31/47 , A61K2300/00
摘要： This invention relates to pharmaceutical combinations of a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceutically acceptable salt thereof; and an antihypertensive agent or a pharmaceutically acceptable salt thereof, optionally in combination with an HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetaliproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal (including a human being either male or female).
摘要翻译：本发明涉及胆固醇酯转移蛋白（CETP）抑制剂或其药学上可接受的盐的药物组合; 和抗高血压剂或其药学上可接受的盐，任选地与HMG CoA还原酶抑制剂或其药学上可接受的盐组合，含有这些组合的试剂盒和使用这些组合的方法来治疗动脉粥样硬化，外周血管疾病，血脂异常，高脂血症，高脂蛋白血症，高胆固醇血症，高甘油三酯血症，家族性高胆固醇血症，心血管疾病，心绞痛，局部缺血，心脏缺血，中风，心肌梗塞，再灌注损伤，血管生成素再狭窄，高血压，糖尿病血管并发症，肥胖症或内毒素血症男性或女性）。

9. 发明申请

US20050245570A1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines 审中-公开
标题翻译： 4-羧基氨基-2-取代-1,2,3,4-四氢喹啉
公开(公告)号：US20050245570A1
公开(公告)日：2005-11-03
申请号：US11152753
申请日：2005-06-13
申请人： Michael DeNinno , George Magnus-Aryitey , Roger Ruggeri , Ronald Wester
发明人： Michael DeNinno , George Magnus-Aryitey , Roger Ruggeri , Ronald Wester
IPC分类号： A61K45/00 , A61K31/192 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/404 , A61K31/405 , A61K31/4418 , A61K31/47 , A61K31/4706 , A61K31/4709 , A61K45/06 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P35/00 , A61P39/02 , A61P43/00 , C07D20060101 , C07D215/00 , C07D215/38 , C07D215/42 , C07D215/48 , C07D221/16 , C07D409/04 , C07D409/12
CPC分类号： C07D409/04 , A61K31/47 , C07D215/42 , C07D215/48 , C07D221/16 , C07D409/12
摘要： Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
摘要翻译：胆固醇酯转移蛋白抑制剂，含有这些抑制剂的药物组合物以及这些抑制剂用于提高某些血浆脂质水平（包括高密度脂蛋白胆固醇）并降低某些其他血浆脂质水平的用途，例如LDL-胆固醇和甘油三酯，并因此治疗 HDL胆固醇水平升高和/或LDL-胆固醇和甘油三酯水平升高的疾病，如一些哺乳动物，包括人类的动脉粥样硬化和心血管疾病。

10. 发明申请

US20090239865A1 DIBENZYL AMINE COMPOUNDS AND DERIVATIVES 审中-公开
标题翻译：二苯胺化合物和衍生物
公开(公告)号：US20090239865A1
公开(公告)日：2009-09-24
申请号：US11719885
申请日：2005-11-21
申请人： George Chang , Mary Didiuk , Peter Dorff , Ravi Garigipati , Wenhua Jiao , Bruce Lefker , David Perry , Roger Ruggeri , Toby Underwood
发明人： George Chang , Mary Didiuk , Peter Dorff , Ravi Garigipati , Wenhua Jiao , Bruce Lefker , David Perry , Roger Ruggeri , Toby Underwood
IPC分类号： A61K31/5377 , C07D257/06 , A61K31/41 , A61K31/4439 , C07D401/14 , C07D413/14 , A61P9/10
CPC分类号： C07D401/12 , C07D231/12 , C07D257/06 , C07D403/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04
摘要： Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
摘要翻译：二苄基胺化合物和衍生物，含有这些化合物的药物组合物以及这些化合物用于提高某些血浆脂质水平（包括高密度脂蛋白胆固醇）并降低某些其他血浆脂质水平的用途，例如LDL-胆固醇和甘油三酸酯，并因此治疗 HDL胆固醇水平升高和/或LDL-胆固醇和甘油三酯水平升高的疾病，如一些哺乳动物，包括人类的动脉粥样硬化和心血管疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式